Depression research published in 2025 - The Consciousness Library

Book Review: Mindfulness-Based Cognitive Therapy for Depression

University of Colombo Review December 31, 2025 Nikapitiye Nandarathana

No abstract available

Integration of the Buddhist Concept of Non-Self (Anatta) in Counselling and Psychotherapy Addressing Distress, Anxiety, and Depression: A Review

Pravacana December 31, 2025 Gomila Gunalankara

The non-self (anatta) concept is a distinctive and psychologically vital teaching in Buddhist philosophy. Scholars and psychotherapists working in mindfulness interventions draw on various Buddhist teachings and practices in clinical settings, and many empirical studies demonstrate their effectiveness. This study aimed to investigate the significance of integrating the non-self concept into...

DOI: 10.4038/p.v16i2.66 Full text

Transcriptional Signatures of Mitochondrial Metabolism Predict Esketamine-Induced rACC Structural Changes in Adolescent Major Depression.

Journal of the American Academy of Child & Adolescent Psychiatry December 31, 2025 Yanling Zhou, Weicheng Li, Xiaofeng Lan et al.

Objective: To investigate neurobiological mechanisms through which esketamine produces rapid antidepressant effects in adolescents with major depressive disorder (MDD), focusing on structural changes in the rostral anterior cingulate cortex (rACC) and associated molecular pathways. Method: A total of 49 adolescents (13-18 years of age) with DSM-5 MDD were randomized to receive intravenous...

DOI: 10.1016/j.jaac.2025.12.011 Esketamine Adolescent depression Transcriptomics Mitochondrial metabolism +1

Effect of Nurse-Delivered Mindfulness-Based Stress Reduction on Postpartum Depression among Primiparous Women: A Randomized Controlled Trial

Al-Turath Journal of Nursing December 31, 2025 Hala S. Abduwahid

Background: Postpartum depression affects 10-20% of new mothers. Non-pharmacological interventions are preferred by breastfeeding mothers, yet evidence for mindfulness-based approaches remains limited. Objective: To evaluate nurse-delivered Mindfulness-Based Stress Reduction on depressive symptoms and stress biomarkers among primiparous mothers with elevated PPD risk. Methods: Single-center...

DOI: 10.63964/atjn.2025.4..4

Ketamine, TMS and ECT for Bipolar Depression

December 31, 2025 Chris Aiken

Ketamines should be used cautiously in bipolar disorder due to its potential to trigger psychosis, and is best reserved for short-term (one-month) treatment of severe depression that might otherwise require hospitalization. While both ECT and TMS are effective for bipolar depression, ECT acts faster and is preferred for more severe cases with psychotic features, with studies showing remission...

DOI: 10.64239/pi-vl10011

Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production.

World journal of microbiology & biotechnology December 31, 2025 José Islas-Vargas, Silvia Armenta, Ángeles Alitzel Rivera-Román et al. 2 citations

Psilocybin, a tryptamine-derived alkaloid from Psilocybe mushrooms, has emerged as a high-value biopharmaceutical candidate due to its promising applications in mental health. While clinical studies highlight its rapid and sustained antidepressant effects, current challenges lie in achieving scalable, reproducible, and cost-effective production to meet growing research and therapeutic demand....

DOI: 10.1007/s11274-025-04758-0 Full text Major depressive disorder Psilocybin Biotechnological production Metabolic engineering

Adenosine as the metabolic common path of rapid antidepressant action: The coffee paradox.

Brain medicine December 31, 2025 Julio Licinio, Ma-Li Wong 3 citations

Yue, Luo, and colleagues discovered that adenosine signalling is the common underlying mechanism of rapid acting antidepressant therapies, unifying the effects of ketamine, ECT and acute intermittent hypoxia. They use genetically encoded sensors, along with extensive mechanistic dissection, to show that all three induce adenosine surges in mood-regulatory circuits via A1 and A2A receptor...

DOI: 10.61373/bm025c.0134 Full text Depression Ketamine Adenosine Antidepressants +2

Evaluating the Efficacy of Mindfulness-Based Cognitive Therapy in Alleviating Depressive Symptoms, Reducing Rumination, and Preventing Relapse Among the Institutionalized Patients in Nigeria: A Randomized Controlled Trial.

International Journal of Social Psychiatry December 29, 2025 Zulkiflu Musa Argungu, Ali Alhaiti, Ebtesam Abdulrahman Jibreel

Depression is a serious issue in the world, affecting over 350 million people. Although it may present at any age, adolescence to early adulthood is the most common age of onset, and females are affected twice as much as males. Rumination is a specific known risk factor for the onset, severity, prolongation, and relapse of depression. Relapse prevention in recurrent depression is a significant...

DOI: 10.1177/00207640251405457 Full text Depression Mindfulness-based cognitive therapy Patient relapse prevention Randomized controlled trial +1

Effectiveness of Intranasal Esketamine on Suicidal Ideation and Depressive Symptoms in Patients with Treatment-Resistant Depression: A Longitudinal Study

Journal of Clinical Medicine December 29, 2025 Matteo Leonardi, Alice Frediani, Mauro Angeletti et al.

Background: Suicidal ideation (SI) represents a clinical challenge in patients with treatment-resistant depression (TRD), and the management of this condition should be as rapid and effective as possible. Intranasal Esketamine has shown promise in patients with TRD due to its rapid onset of action on both SI and depressive symptoms. Since this medication has been recently approved, real-world...

DOI: 10.3390/jcm15010250 Treatment-resistant depression Major depressive disorder Suicidal ideation Depression economics +7

Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine

Computational and Structural Biotechnology Journal December 29, 2025 Silvia Tapia-Gonzalez, Josue G. Yagüe, George E. Barreto

Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventional antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor, require weeks to exert therapeutic effects, whereas ketamine and esketamine act rapidly via glutamatergic modulation. These drugs may also converge on the inhibition...

DOI: 10.1016/j.csbj.2025.12.023 Major depressive disorder Ketamine Antidepressant Neurotrophic factors +10

Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials

Journal of Clinical Medicine December 29, 2025 Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al. 2 citations

Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...

DOI: 10.3390/jcm15010253 MDMA Psilocybin Major depressive disorder Alcohol use disorder +8

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

International Journal of Molecular Sciences December 28, 2025 Mateusz Kowalczyk, David Aebisher, Jakub Szpara et al. 3 citations

Depression is a common, debilitating, and potentially life-threatening mental disorder affecting individuals across all age groups and populations. It represents one of the major challenges of contemporary medicine. It is estimated that more than 300 million people worldwide are affected, and patients with major depressive disorder (MDD) exhibit a significantly increased risk of suicide,...

DOI: 10.3390/ijms27010344 Major depressive disorder Treatment-resistant depression Neuromodulation Monoaminergic +10

The Emerging Role of Ketamine and Esketamine in the Concurrent Management of Pain and Depression in Cancer Patients: Evidence and Implications for Practice

Journal of Pain & Palliative Care Pharmacotherapy December 27, 2025 Shannon Moriarty, Anna Dushenkov, Kathleen M. Frey

Cancer patients frequently experience pain and depression, yet current guidelines address these conditions separately and do not recommend a single agent for concurrent management. Ketamine and its S-enantiomer esketamine, through N-methyl-D-aspartate receptor antagonism and glutamate modulation, may offer dual benefit. This paper examined ten clinical studies published between 2018 and 2024...

DOI: 10.1080/15360288.2025.2607541 Ketamine Treatment-resistant depression Major depressive disorder Adverse effect +10

Patients’ Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives

Journal of Clinical Medicine December 25, 2025 Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik 1 citation

Treatment-resistant depression (TRD) remains a significant public-health challenge, with many patients failing to respond to conventional therapies. Ketamine has emerged as a rapid-acting intervention, but quantitative outcomes alone do not capture patients' lived experiences, which shape engagement, acceptability, and adherence. We conducted a narrative review of qualitative and mixed-methods...

DOI: 10.3390/jcm15010150 Ketamine Thematic analysis Qualitative research Narrative review +6

Mechanisms of sustained mindfulness practice in stroke survivors: A critical realist secondary analysis of the HEADS: UP intervention.

Complementary Therapies in Clinical Practice December 23, 2025 Naomi E. Clark, Ben Parkinson, Xu Wang et al.

Post-stroke anxiety and depression symptoms are common after stroke and can persist long-term. Despite this, there is a lack of long-term psychological support for post-stroke anxiety and depression. Mindfulness-based interventions are emerging as feasible, acceptable and potentially effective interventions for post-stroke anxiety and depression. Sustained use of mindfulness practice can help...

DOI: 10.1016/j.ctcp.2025.102041 Full text Anxiety Depression Mindfulness Maintenance +2

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study

Psychedelic Medicine December 23, 2025 Anthony L. Back, Bonnie A. Mcgregor, Lindsay Billingsley et al. 1 citation

Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community. Purpose: This technical report describes a group facilitation model developed for an food and drug administration...

DOI: 10.1177/28314425251404460 Psilocybin Anxiety Facilitation Clinical trial +10

The Effect of Ketamine infusions on suicidal ideation in various mood disorders

JPMA. The Journal of the Pakistan Medical Association December 20, 2025 Muhammad Bin Mobin, Zainab Abid, Sameen Saqib

Borderline Personality Disorder (BPD) is characterised by altered perception of self, mood changes, and suicidal ideation. The traditional treatments of BPD, including psychotherapy, fail to provide an immediate response in susceptible patients. However, recent literature has shed light on the use of Ketamine as intervention for suicidal ideation in BPD patients, as well as for patients with...

DOI: 10.47391/jpma.21482 Ketamine Major depressive disorder Suicidal ideation Borderline personality disorder +5

Magic mushrooms and mood: exploring Psilocybin as a depression treatment

JPMA. The Journal of the Pakistan Medical Association December 20, 2025 Maria Rasool, Taha Hannan, Muhammad Imam

Dear Editor, In view of ongoing global research on mental health, especially Major Depressive Disorder, we would like to draw attention to a psychedelic substance, Psilocybin, which has been emerging as a viable treatment option for MDD. Psilocybin is a psychedelic compound derived from certain mushrooms that acts on Serotonergic receptors (primarily 5HT-2A). Psychedelic substances have...

DOI: 10.47391/jpma.30858 Psilocybin Serotonergic Major depressive disorder Hallucinogen +8

Intestinal γδ T17-IL-17A signaling disrupts hippocampal mitophagy in stress-induced depression and is restored by arketamine.

Journal of Neuroinflammation December 18, 2025 Mengqi Han, Bing Xie, Yuan Yu et al.

Chronic stress precipitates depression, yet how gut-immune-brain interactions translate stress into mood pathology remains unclear. We tested the hypothesis that stress-primed small intestinal γδ T cells drive hippocampal mitochondrial dysfunction and depression-like behavior via interleukin-17A (IL-1A). In mice exposed to chronic restraint stress (CRS), we combined behavioral assays...

DOI: 10.1186/s12974-025-03656-4 Full text Depression Ketamine Chronic restraint stress Gut-brain axis +2

Psilocybin reporting in media (PRiMe) for the treatment of depression

Irish Journal of Psychological Medicine December 18, 2025 Gurjot Brar, T. R. Jun. Burke, Andrew Gribben et al.

Abstract Objectives: Interest in psilocybin as a treatment for depression has risen over the past decade, fuelled by promising clinical trials and a rapidly evolving regulatory landscape. Media coverage plays a critical role in shaping public perceptions, yet little is known about how psilocybin is portrayed in global anglophone online news for the treatment of depression. Methods: This study...

DOI: 10.1017/ipm.2025.10142 Full text Psilocybin Foundation evidence Perception Depression economics +4

Studies